Health Care & Life Sciences » Pharmaceuticals | Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
864
879
288
2,408
2,404
4,152
Depreciation, Depletion & Amortization
1,363
1,663
2,366
2,866
2,858
2,819
Other Funds
173
141
245
683
67
2,858
Funds from Operations
1,420
2,872
2,920
2,100
1,336
1,381
Changes in Working Capital
378
629
822
110
844
18
Net Operating Cash Flow
1,042
2,243
2,098
1,990
2,180
1,399
Capital Expenditures
185
471
303
291
336
Sale of Fixed Assets & Businesses
41
1,492
13
199
3,253
Purchase/Sale of Investments
17
19
17
16
5
Net Investing Cash Flow
5,380
100
15,572
125
2,887
Issuance/Reduction of Debt, Net
1,939
2,267
12,639
1,216
4,786
Net Financing Cash Flow
4,028
2,392
13,785
1,866
4,853
Net Change in Cash
316
278
280
55
255
Free Cash Flow
927
1,951
1,862
1,755
2,009
Deferred Taxes & Investment Tax Credit
516
76
7
236
4,386
144
Net Assets from Acquisitions
5,254
1,103
15,457
19
-
Other Sources
-
-
185
-
-
Change in Capital Stock
2,262
17
1,391
33
-
Exchange Rate Effect
5
29
30
54
41
Other Uses
-
-
26
30
25

About Valeant Pharmaceuticals International

View Profile
Address
2150 St. Elzéar Boulevard West
Laval Québec H7L 4A8
Canada
Employees -
Website http://www.bauschhealth.com
Updated 07/08/2019
Bausch Health Cos. , Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.